Search CTL/CD8+ T-Cell Epitope Database

Found 7 matching records:

Displaying record number 53725

HXB2 Location	Nef(119-127) DNA(9151..9177)	Nef Epitope Map
Author Location	Nef(119-127)
Epitope	`GYFPDWQNY`	Epitope Alignment
		Show epitope variants
Subtype	B, CRF02_AG
Species (MHC/HLA)	human(A24)
Immunogen	HIV-1 infection
Country	Cote D'Ivoire
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	subtype comparisons

Notes

CD8+ T-cells from HIV-1 CRF02_AG-infected Ivorians could recognize clade B epitopes. No difference was observed in the number of recognized peptide pools between nine French subtype B infected study subjects, and nine CRF02_AG infected Ivorian subjects.
This epitope was recognized by 0/9 CRF02_AG-infected Ivorians, and 1/9 B-infected French subjects. It was invariant among 5 French subjects,including the one that reacted with the epitope, and had single amino acid substitutions in 4/8 Ivorians.

References

Inwoley2005 André Inwoley, Patricia Recordon-Pinson, Marion Dupuis, Jessintha Gaston, Mathieu Genête, Albert Minga, Franck Letourneur, François Rouet, Jeannine Choppin, Hervé Fleury, Jean-Gérard Guillet, Muriel Andrieu, and ANRS 1220 PRIMO-CI Study Group. Cross-Clade Conservation of HIV Type 1 Nef Immunodominant Regions Recognized by CD8+ T Cells of HIV Type 1 CRF02\_AG-Infected Ivorian (West Africa). AIDS Res. Hum. Retroviruses, 21(7):620-628, Jul 2005. PubMed ID: 16060833. Show all entries for this paper.

Displaying record number 56231

HXB2 Location	Nef(119-127) DNA(9151..9177)	Nef Epitope Map
Author Location
Epitope	`GYFPDWQNY`	Epitope Alignment
Subtype	C
Species (MHC/HLA)	human(A24)
Immunogen	HIV-1 infection
Country	South Africa
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay
Keywords	rate of progression, optimal epitope

Notes

47 HIV-1 subtype C infected patients were followed longitudinally to determine whether there was a relation between magnitude and breadth of CTL responses in primary, acute infection (measured by IFN-gamma ELISpot) and disease progression (measured as viral load at 12 months). CTL responses to Nef were dominant (targeting 6 epitopic regions), followed by responses to Gag, Pol, Rev, Vpr, Env, Vpu, Vif and finally Tat.
GYFPDWQNY is a known HLA-A24-restricted epitope that is part of peptide WVYHTQGYFPDWQNYTPGP which elicited responses in 3/25 patients, and which belongs to peptide pool 3 that accounted for over 70% of Nef responses.

References

Gray2009 Clive M. Gray, Mandla Mlotshwa, Catherine Riou, Tiyani Mathebula, Debra de Assis Rosa, Tumelo Mashishi, Cathal Seoighe, Nobubelo Ngandu, Francois van Loggerenberg, Lynn Morris, Koleka Mlisana, Carolyn Williamson, Salim Abdool Karim, and CAPRISA 002 Acute Infection Study Team. Human Immunodeficiency Virus-Specific gamma Interferon Enzyme-Linked Immunospot Assay Responses Targeting Specific Regions of the Proteome during Primary Subtype C Infection Are Poor Predictors of the Course of Viremia and Set Point. J. Virol., 83(1):470-478, Jan 2009. PubMed ID: 18945774. Show all entries for this paper.

Displaying record number 59417

HXB2 Location	Nef(119-127) DNA(9151..9177)	Nef Epitope Map
Author Location	Nef
Epitope	`GYFPDWQNY`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*58)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, immunodominance, novel epitope

Notes

The study compared B*27/*57-positive versus negative patients among a cohort of long-term nonprogressors and elite controllers with B*27/B*57-negative progressors. Overlapping 15-mers that elicited responses in multiple patients, or were among the strongest responses in a single patient, were narrowed down by truncation to define optimal epitopes, 11 of which were novel.
GYFPDWQNY was recognized by 1/4 LTNP/EC, and 1/1 had it as a dominant response. The restricting HLA (B*58) was confirmed experimentally.

References

Migueles2015 Stephen A. Migueles, Daniel Mendoza, Matthew G. Zimmerman, Kelly M. Martins, Sushila A. Toulmin, Elizabeth P. Kelly, Bennett A. Peterson, Sarah A. Johnson, Eric Galson, Kate O. Poropatich, Andy Patamawenu, Hiromi Imamichi, Alexander Ober, Catherine A. Rehm, Sara Jones, Claire W. Hallahan, Dean A. Follmann, and Mark Connors. CD8+ T-Cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types. EBioMedicine, 2(1):46-58, Jan 2015. PubMed ID: 26137533. Show all entries for this paper.

Displaying record number 61748

HXB2 Location	Nef(119-127) DNA(9151..9177)	Nef Epitope Map
Author Location	Nef(119-127)
Epitope	`GYFPDWQNY`	Epitope Alignment
Epitope Name	GY9
Species (MHC/HLA)	human(B*58)
Immunogen
Experimental methods
Keywords	optimal epitope

Notes

C. Brander notes this as a B*58-restricted Nef epitope (Migueles2015).

References

Llano2019 Anuska Llano, Samandhy Cedeño, Sandra Silva Arrieta, and Christian Brander. The 2019 Optimal HIV CTL Epitopes Update: Growing Diversity in Epitope Length and HLA restriction. 2019. Show all entries for this paper.

Displaying record number 59418

HXB2 Location	Nef(119-127) DNA(9151..9177)	Nef Epitope Map
Author Location	Nef
Epitope	`GYFPDWQNY`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(Cw*02)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, immunodominance, novel epitope

Notes

The study compared B*27/*57-positive versus negative patients among a cohort of long-term nonprogressors and elite controllers with B*27/B*57-negative progressors. Overlapping 15-mers that elicited responses in multiple patients, or were among the strongest responses in a single patient, were narrowed down by truncation to define optimal epitopes, 11 of which were novel.
GYFPDWQNY was recognized by 2/7 LTNP/EC, and 1/2 had it as a dominant response. The restricting HLA (Cw*02) was confirmed experimentally.

References

Displaying record number 61749

HXB2 Location	Nef(119-127) DNA(9151..9177)	Nef Epitope Map
Author Location	Nef(119-127)
Epitope	`GYFPDWQNY`	Epitope Alignment
Epitope Name	GY9
Species (MHC/HLA)	human(Cw*02)
Immunogen
Experimental methods
Keywords	optimal epitope

Notes

C. Brander notes this as a Cw*02-restricted Nef epitope (Migueles2015).

References

Displaying record number 56968

HXB2 Location	Nef(119-127) DNA(9151..9177)	Nef Epitope Map
Author Location	Nef
Epitope	`GYFPDWQNY`	Epitope Alignment
Subtype	C, D
Species (MHC/HLA)	human
Immunogen	HIV-1 infection
Country	Sweden
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	subtype comparisons, computational epitope prediction, vaccine antigen design

Notes

From HIV-1 sequences of multiple subtypes, bioinformatic prediction generated 174 CTL epitopes from Gag, Pol, Nef, Env and Tat restricted by HLA supertypes A1, A2, A3, A24, B7, B44 and B58; 10 previously-published A2- and B58-restricted epitopes were also included. Of these 184 epitopes, 113 were recognized experimentally in serum from 31 HIV+ patients.
While Gag, Pol, Env and Nef were highly immunogenic, only 38% of Tat epitopes elicited a response.
GYFPDWQNY was a predicted epitope restricted by A24 supertype. 2/31 patient(s) responded to it; 1 responding patient was known to carry an allele of A24 supertype. Responding patients were infected with HIV clade(s) C, D.

References

Perez2008 Carina L. Pérez, Mette V. Larsen, Rasmus Gustafsson, Melissa M. Norström, Ann Atlas, Douglas F. Nixon, Morten Nielsen, Ole Lund, and Annika C. Karlsson. Broadly Immunogenic HLA Class I Supertype-Restricted Elite CTL Epitopes Recognized in a Diverse Population Infected with Different HIV-1 Subtypes. J. Immunol., 180(7):5092-5100, 1 Apr 2008. PubMed ID: 18354235. Show all entries for this paper.